期刊
JOURNAL OF MOLECULAR NEUROSCIENCE
卷 45, 期 3, 页码 366-371出版社
HUMANA PRESS INC
DOI: 10.1007/s12031-011-9597-0
关键词
Frontotemporal lobar degeneration; Biomarker; Cerebrospinal fluid; Neuroimaging
资金
- NIH [AG15116, AG17586, NS44266, NS53488, AG32953]
Recent findings assessing the utility of biomarkers are reviewed that help identify the basis for disease in patients with frontotemporal lobar degeneration (FTLD) spectrum pathology. Biofluid studies identify about 15% of patients with FTLD due to a genetic mutation that is associated with the specific histopathologic features of TDP-43 or a tauopathy. Other genetically based risk factors and targeted proteomic searches of plasma and cerebrospinal fluid have suggested additional markers that may be useful in sporadic cases of FTLD. While progress has been made in developing biomarkers for FTLD, additional work is needed to extend these advances so that the histopathologic abnormality causing FTLD can be specified in an individual patient.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据